Gamma delta T cells are not the mainstream soldiers of adaptive immunity. Unlike conventional alpha beta T cells, they do not require recognition of peptide antigens presented by the major histocompatibility complex, the molecular display system that tumors frequently shut down to escape immune detection. This MHC independence gives gamma delta T cells an inherent advantage in solid tumors such as lung cancer, where downregulation of antigen presentation machinery is one of the dominant escape strategies. The cells are also unusually enriched in pulmonary mucosal tissue, positioning them as first-line sentinels of the lung. When functioning in their cytotoxic type 1 state, they destroy malignant cells through the release of perforin and granzymes, pore-forming and proteolytic molecules that induce target cell death, while simultaneously secreting interferon-gamma to amplify inflammatory anti-tumor signaling across the microenvironment.

The paradox, as the review makes clear, is that the very plasticity that makes gamma delta T cells versatile also makes them vulnerable to subversion. Under the influence of commensal microbiota-driven inflammatory signals, specifically interleukin-1 beta and interleukin-23, tissue-resident subsets can be polarized into a pro-tumorigenic type 17 phenotype. These interleukin-17-secreting cells recruit neutrophils into the tumor and foster an inflammatory milieu that accelerates cancer progression rather than restraining it. In other words, the same family of lymphocytes can function as a double-edged sword in non-small cell lung cancer, and which edge cuts depends on the local context of cytokines, metabolites, and microbial products. The review emphasizes that understanding the signals governing this fate decision is essential before gamma delta T cells can be reliably exploited therapeutically.

A central mechanistic thread in the review concerns the butyrophilin 3A1 and 2A1 phosphoantigen recognition axis. Butyrophilins are molecules related to the B7 costimulatory family, and in humans BTN3A1 in particular acts as an intracellular sensor for phosphoantigens, small phosphorylated metabolites that accumulate in transformed cells as a byproduct of dysregulated mevalonate pathway activity. When phosphoantigens bind inside the cell, BTN3A1 undergoes conformational changes that trigger activation of gamma delta T cells expressing a specific T cell receptor lineage, most notably the Vgamma9Vdelta2 subset that predominates in human blood. This recognition pathway is a major reason why gamma delta T cells can sense and kill tumor cells without conventional antigen presentation, and it has been the foundation for several clinical strategies, including aminobisphosphonate drugs that elevate intracellular phosphoantigen levels to stimulate these cells in vivo. The authors underscore that manipulating this axis, while promising, must contend with the reality of the tumor microenvironment, which actively degrades the functional competence of infiltrating lymphocytes.

That hostile environment is the second pillar of the review. The lung tumor microenvironment imposes layered barriers that fall into three broad categories: metabolic, epigenetic, and physical. Metabolically, solid tumors are nutrient-deprived battlefields where rapidly dividing cancer cells consume glucose, glutamine, and essential amino acids, leaving infiltrating immune cells starved and functionally exhausted. Gamma delta T cells undergo metabolic reprogramming under these conditions, and their effector function depends on maintaining mitochondrial fitness and glycolytic capacity, both of which are compromised in the hypoxic, lactate-rich interior of a tumor. Epigenetically, chronic exposure to immunosuppressive cytokines and checkpoint ligands drives stable transcriptional silencing of effector programs, a form of immune senescence that persists even when cells are removed from the tumor. Physically, the dense stroma, abnormal vasculature, and elevated interstitial pressure of lung tumors impede trafficking and infiltration, so that even potent gamma delta cells may never reach their targets in sufficient numbers.

Against this backdrop, the review surveys emerging engineering strategies designed to restore or enhance gamma delta T cell efficacy. Among the most clinically consequential is the development of allogeneic cellular products, meaning gamma delta T cells derived from healthy donors rather than patients themselves. Because these cells do not depend on MHC matching and carry a low risk of graft-versus-host disease compared with conventional allogeneic alpha beta T cells, they are natural candidates for off-the-shelf immunotherapy, a manufacturing and logistics advantage that could democratize access to advanced cellular medicine. Autologous approaches, in which a patient’s own gamma delta cells are expanded and activated outside the body before reinfusion, remain important, but they are constrained by the fact that cells harvested from cancer patients are often already exhausted or corrupted by tumor-induced dysfunction.

Epigenetic priming is presented as a complementary strategy with particular relevance to reversing immune senescence. By manipulating chromatin-modifying enzymes, for example through pharmacological inhibition of DNA methyltransferases or histone deacetylases, researchers can reactivate silenced effector genes and restore the cytotoxic identity of exhausted gamma delta T cells. The review suggests that epigenetic priming could be applied either ex vivo during cell manufacturing or in vivo as part of combination regimens, effectively wiping the dysfunctional epigenetic memory that the tumor microenvironment imposes. This approach acknowledges a growing consensus in immunology that functional T cell states are not fixed lineages but recoverable programs, provided the right transcriptional and chromatin landscape can be reinstated.

The third strategic pillar is microbiota-directed polarization. Given that commensal microbial signals can push gamma delta T cells toward the pro-tumorigenic type 17 fate through interleukin-1 beta and interleukin-23, the review proposes deliberately shaping the microbiome or intervening in downstream cytokine signaling to stabilize durable anti-tumor type 1 phenotypes instead. This could involve antibiotics, probiotics, dietary interventions, or targeted blockade of the interleukin-17 axis, an approach already validated in other inflammatory diseases. The idea that the gut and airway microbiota exert systemic control over tumor immunity has gained substantial traction in recent years, and the review situates gamma delta T cell biology squarely within this emerging framework of microbiota-immune crosstalk, arguing that polarization control may be as important as cell activation or expansion.

The translational roadmap that Wang and Xiao propose integrates these elements into a coherent pipeline: allogeneic off-the-shelf cellular engineering to solve supply and logistics, metabolic priming to reverse immune senescence and restore cytotoxic metabolism, and microbiota-directed polarization to lock in stable anti-tumor function. Combination approaches, including pairing engineered gamma delta cells with checkpoint inhibitors, bisphosphonates, or metabolic modulators, are framed as the likely path to clinical impact. The ultimate goal, the authors write, is to overcome immune escape driven by impaired antigen presentation and to advance precision immunotherapy for non-small cell lung cancer, a disease in which the current immunotherapy paradigm leaves too many patients behind. Because gamma delta T cells can recognize stressed and transformed cells through stress ligands and phosphoantigen sensing rather than a single tumor antigen, they may also offer a broader and more durable response than approaches dependent on a single target.

The review arrives at a moment of genuine momentum for gamma delta T cell therapeutics, with multiple clinical trials underway across hematologic malignancies and solid tumors, and with growing commercial interest in allogeneic gamma delta platforms. For lung cancer, where the tumor microenvironment is among the most immunosuppressive and physically hostile of any solid malignancy, the stakes are particularly high. The authors’ synthesis makes a persuasive case that the field’s next advances will come not from simply arming these cells, but from understanding and controlling the environmental forces that determine whether they fight for the patient or for the tumor. As the mechanistic picture sharpens, the double-edged nature of gamma delta T cells may yet prove to be less a liability than an opportunity, provided clinicians and engineers learn to grip the correct handle. The work was supported by the Changde Science and Technology Innovation Guidance Program under Grant No. 2025ZD145, and the article is published open access, making the full mechanistic analysis available to researchers and clinicians worldwide.

Immune checkpoint inhibitors have redefined therapeutic paradigms by unleashing the immune system’s latent capacity to recognize and annihilate cancer cells. However, resistance to ICIs remains a critical bottleneck in clinical success, with many patients experiencing suboptimal responses or relapse. Mounting evidence implicates the gut microbiome—an extraordinarily diverse and dynamic ecosystem of trillions of microorganisms—in modulating immune function and influencing therapeutic outcomes. FMT, the transfer of fecal material containing microbial communities from healthy donors to patients, has surfaced as a compelling strategy to recalibrate impaired microbiota and restore immune responsiveness, yet its clinical application in oncology is fraught with complexities.

Dr. Luo emphasizes that the impact of FMT on enhancing ICI therapy is far from uniform. “Our review highlights a spectrum of responses — ranging from striking clinical remission in certain melanoma patients to unexpected adverse outcomes in others,” he explains. Some landmark melanoma studies demonstrate that approximately 40% of patients who previously showed resistance to immunotherapy regained sensitivity post-FMT, a finding that ignited optimism for microbiome-centered interventions. However, contradictory trials reveal that specific bacterial consortia delivered via FMT can paradoxically dampen immune activation, emphasizing that the microbial realm is not a one-size-fits-all remedy but rather a highly individualized and complex influencer of cancer immunology.

Central to the review’s insights is the recognition that the gut microbiome functions as an intricate ecological network, where compositional and functional attributes of microbial taxa orchestrate distinct immunomodulatory effects. Beneficial commensals have been shown to potentiate cytotoxic T cell activity and facilitate infiltration of effector immune cells into the tumor microenvironment. Conversely, adverse bacteria may foster regulatory immune populations, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), which blunt antitumor immunity and promote tumor persistence. These antagonistic interactions underscore the challenge of engineering microbial consortia that predictably augment immunotherapy.

Moreover, individual patient factors, including baseline microbiome diversity, genetic predispositions, diet, and concurrent medications, intricately influence FMT outcomes. “We were particularly surprised by the observation that identical bacterial species can exert diametrically opposed effects depending on host context,” notes Dr. Luo. This revelation pinpoints the paramount necessity for personalized microbiome therapeutics that accommodate the host’s unique biological landscape rather than indiscriminately applying generalized microbial formulations.

Another pivotal aspect highlighted in the review concerns donor selection criteria. The choice of donor microbiota emerges as a critical determinant of therapeutic success or failure. Donors with high microbial diversity and enriched populations of immunostimulatory bacteria tend to produce superior clinical outcomes. Nonetheless, the absence of standardized donor screening protocols and microbial characterization methodologies presents a significant hurdle in developing reproducible and reliable FMT-based immunotherapy adjuvants.

The authors also discuss the underlying mechanistic pathways through which gut bacteria interface with immune checkpoint blockade. Specific microbial metabolites, such as short-chain fatty acids (SCFAs), and bacterial-derived molecular patterns engage pattern recognition receptors on immune cells, modulating downstream signaling pathways that either prime antitumor immunity or facilitate immune evasion. Metabolomic and transcriptomic profiling of patient samples pre- and post-FMT further unravel the complex crosstalk between microbial metabolic outputs and host immune gene expression networks.

From a translational perspective, the review strongly advocates for the initiation of large-scale, multicenter clinical trials to systematically evaluate FMT efficacy and safety in conjunction with ICIs across diverse cancer types. Such trials must integrate rigorous microbiome sequencing, immune phenotyping, and functional assays to delineate biomarkers predictive of response and adverse events. Integration of computational models to predict optimal donor-recipient microbial matches could revolutionize patient stratification and treatment personalization.

Emerging technological advances in synthetic biology and microbial engineering offer tantalizing prospects to refine FMT approaches. Designer microbial consortia, genetically optimized to amplify antitumor immune mechanisms while minimizing off-target effects, represent the next evolutionary step beyond crude fecal transfers. Such innovations may overcome current limitations by allowing precise modulation of key immunological pathways and tumor microenvironment conditioning.

Safety considerations remain paramount, given the potential risks associated with transferring pathogenic or deleterious bacteria. The review calls for the development of standardized protocols encompassing donor screening, microbial characterization, and post-treatment monitoring to mitigate risks. Regulatory frameworks must evolve concurrently to oversee the clinical deployment of microbiome-based therapeutics and ensure patient protection.

As the field advances, Dr. Luo envisions a future where oncologists harness the gut microbiome as a precision tool, integrated seamlessly with conventional immunotherapies to transform cancer treatment outcomes. “Our findings illustrate a journey from chaos to order in the realm of fecal microbiota transplantation, highlighting the imperative for nuanced, scientifically grounded approaches to unlock its full potential,” he concludes.

This rigorous review represents a critical inflection point in cancer immunology, offering a roadmap for translating microbiome science into tangible clinical benefits. By elucidating the multifaceted influences of gut bacteria on immune checkpoint inhibitor efficacy, it sets the stage for a new era of microbiome-informed, patient-centric cancer therapies aimed at conquering resistance and achieving durable remissions.

Subject of Research: Cells
Article Title: From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy.
Web References: http://dx.doi.org/10.1080/19490976.2025.2452277
Keywords: Cancer immunoediting